Nexus Pharmaceuticals Plans Manufacturing Complex in Pleasant Prairie, Wisconsin
According to company officials, the company, which specializes in developing innovative processes to manufacture specialty and generic injectable drugs, is investing in a facility which will support the production and supply of injectable drugs in an array of therapeutic areas including anesthesia, oncology, cardiovascular and neurology.
“This investment is needed to drive the continued growth for the U.S. pharmaceutical manufacturing industry,” said Mariam Darsot, CEO. “We would like to thank the Wisconsin Economic Development Corporation, The Milwaukee 7, Kenosha Area Business Alliance and The Village of Pleasant Prairie for their support as we develop our plans for this major expansion project.”
The multi-phase, multi-year project is expected to be completed in ten years, with an estimated investment of $250 million, company officials said. Construction is planned to commence in August 2019 and is expected to be completed in 2021. After the facility and manufacturing processes are approved by the Food and Drug Administration (FDA), commercial production is expected to commence in 2022.
The initial phase 1 investment of $85 million will support a new, three-story manufacturing facility with cutting-edge technology including an advanced isolator system for maximum product protection and sterility; reducing the risk of contamination. The facility will also include multiple lyophilization (freeze-drying) machines to support production of Nexus’ current portfolio and robust pipeline of generic and specialty injectable drugs.
The new 100,000 square foot facility is being designed by Integrated Project Services (IPS) with construction management services being provided by Turner Construction, both of whom have strong backgrounds in design and construction of pharmaceutical manufacturing. The facility will support the Wisconsin economy by creating more than 77 new jobs in fields of high-tech manufacturing and science by 2022.
“As a pharmaceutical company with a significant focus on sterile injectable medicines, Nexus Pharmaceuticals understands the growing patient demand for high quality and accessible generic injections,” said Shahid Ahmed, Chief Scientific Officer. “With the addition of our new manufacturing facility, we are committed to providing a more stable and reliable supply of sterile injectables, a category that is particularly susceptible to drug shortages.”
“This is one of the most significant pharmaceutical investments in Wisconsin in years,” said Governor Tony Evers. “The Village is honored to welcome Nexus Pharmaceuticals to Southeastern Wisconsin,” said Village President Steinbrink. “Nexus is a remarkable company with excellent jobs, strong growth and high values. I am confident that Nexus will find Prairie Highlands Corporate Park in Pleasant Prairie to be an exceptional location to grow their business.”
Front Line: Manufacturers Look to Nontraditional Locations
A Site Selector’s Checklist for Locating in the U.S.
Location USA 2019
2018 Top States for Doing Business: Georgia Ranks #1 Fifth Year in a Row
A Changing Food Manufacturing Industry
2017 Food Processing
2018 Leading Metro Locations: Pacific and Mountain Metros Dominate the List
2019 Gold & Silver Shovel Awards: Recipients Garnered Large Job-Creating and Investment Projects in Diverse Industries